DE2759297C2 - Process for the preparation of 2-oxo-1-pyrrolidine-acetamide - Google Patents

Process for the preparation of 2-oxo-1-pyrrolidine-acetamide

Info

Publication number
DE2759297C2
DE2759297C2 DE2759297A DE2759297A DE2759297C2 DE 2759297 C2 DE2759297 C2 DE 2759297C2 DE 2759297 A DE2759297 A DE 2759297A DE 2759297 A DE2759297 A DE 2759297A DE 2759297 C2 DE2759297 C2 DE 2759297C2
Authority
DE
Germany
Prior art keywords
oxo
acetamide
pyrrolidine
preparation
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2759297A
Other languages
German (de)
Other versions
DE2759297B1 (en
Inventor
Slobodan Dr. Djokic
Branimir Dr. Gaspert
Alfred Dr. 2000 Hamburg Maasboel
Branimir Simunic
Mirjana Dipl.-Ing. Tomic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pliva Farmaceutika dd
Original Assignee
Pliva Farmaceutska Kemijska Prehrambena I Kozmeticka Industrija dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from YU7776A external-priority patent/YU39660B/en
Priority claimed from YU198376A external-priority patent/YU40148B/en
Application filed by Pliva Farmaceutska Kemijska Prehrambena I Kozmeticka Industrija dd filed Critical Pliva Farmaceutska Kemijska Prehrambena I Kozmeticka Industrija dd
Publication of DE2759297B1 publication Critical patent/DE2759297B1/en
Application granted granted Critical
Publication of DE2759297C2 publication Critical patent/DE2759297C2/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/272-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Description

Es ist bekannt, daß das 2-Oxo-l-pyrro!idin-acetamid durch Reaktion von 2-Oxo-pyrrolidin-Na (hergestellt 2-Oxo-pyrrolidin und Na oder NaOH) mitIt is known that 2-oxo-l-pyrro! Idine acetamide by reaction of 2-oxo-pyrrolidine-Na (prepared 2-oxo-pyrrolidine and Na or NaOH) with

2-ChIoracetamid, ferner durch Einwirken von NHj auf 2-Oxo-t-pyrrolidin-essigsäureester oder -chlorid (GB 10 39 113) oder durch thermische Zersetzung ihres Ammoniumsalzes (GB 13 09 692) hergestellt werden kann. Die erwähnte Verbindung zeigt beispielsweise therapeutische Wirkung bei der Behandlung chronischer Störungen der Gehirnfunktion. Sie ist bekannt unter dem generischen Namen Pyracetam.2-chloroacetamide, also by the action of NHj 2-Oxo-t-pyrrolidine acetic acid ester or chloride (GB 10 39 113) or by thermal decomposition of their ammonium salt (GB 13 09 692) can. The compound mentioned shows, for example, a therapeutic effect in the treatment of chronic ones Disorders of brain function. It is known by the generic name of pyracetam.

Es wurde nun gefunden, daß die Verbindung der Formel I auf einfache Weise entsprechend dem folgenden Reaktionsschema hergestellt werden kann:It has now been found that the compound of formula I in a simple manner according to the the following reaction scheme can be produced:

2H2N CH2 CONH, + CICH2 CH, CH2 COCl (II) (III)2H 2 N CH 2 CONH, + CICH 2 CH, CH 2 COCl (II) (III)

CICH, C-H. CH2 CONH CH2 CONH2 (IV)CICH, C - H. CH 2 CONH CH 2 CONH 2 (IV)

HC-I H2N CH2 CONH2 (V)HC - IH 2 N CH 2 CONH 2 (V)

N w N w

CH2CONH2
(I)
CH 2 CONH 2
(I)

Erfindungsgemäß wird Glycinamid in N.N-Dimelhylacetamid gelöst und stufenweise der abgekühlten Lösung des Chlorids der 4-Chlorbuttcrsäure in einem aprotischen organischen Lösungsmittel zugesetzt. Der entstandene Niederschlag des Glycinamidsalzes der Formel V wird zur Regenerierung des Glycinamids filtriert, während das leicht flüchtige Lösungsmittel aus dem Fillrat unter vermindertem Druck entfernt wird. Das Produkt wird unter Zusatz eines geeigneten Lösungsmittels, in welchem das Produkt unlöslich ist. aus dem Rückstand ausgefällt. Das erhaltene 4-Chlorbutyrylglycinamid wird anschließend in Alkohol gelöst und in Gegenwart von Natriumhydroxid oder eines Natriumalkoholtes. oder des basischen Anionenaustauschers Dowex I in 2-Oxo-l-pyrrolicJin-acetamid umge wandelt, welches aus der Reaklionslösung nach Entfernendes Lösungsmittels isoliert wird.According to the invention, glycinamide is converted into N.N-dimelhylacetamide dissolved and gradually the cooled solution of the chloride of 4-chlorobutyric acid in one aprotic organic solvents added. The resulting precipitate of the glycinamide salt Formula V is filtered to regenerate the glycinamide, while the volatile solvent is removed the fillrate is removed under reduced pressure. The product is made with the addition of a suitable Solvent in which the product is insoluble. precipitated from the residue. The 4-chlorobutyrylglycine amide obtained is then dissolved in alcohol and in the presence of sodium hydroxide or one Sodium alcohol. or the basic anion exchanger Dowex I in 2-oxo-l-pyrrolicJin-acetamide vice versa converts, which is isolated from the reaction solution after removal of the solvent.

Der Vorteil des erfindungsgemäßen Verfahrens besteht dann, daß die Anwendung von Natrium b/w Natriumh>drid und das Verfahren mit dem intermedia ren Ammoniuiraalz vermieden wird, so daß das effindUhgsgemäße Verfahren einfach durchzuführen ist. Ferner sind! die Ausgangsstoffe leicht zugänglich,The advantage of the method according to the invention is that the use of sodium b / w Sodium h> drid and the procedure with the intermedia ren ammonium salt is avoided, so that the Effective procedure is easy to carry out. Furthermore are! the starting materials easily accessible,

Herstellung der Ausgangsverbindung
4-Chlorbuiyrylglycifiamid der Formel IV
Preparation of the starting compound
4-Chlorbuiyrylglycifiamid of the formula IV

11,1g (0,15MoI) Glycinamid werdeil in 50 ml N.N-Dimelhylacetäifiid unter leichtem Erwärmen gelöst und zu der Lösung stufenweise 1055 g (0.075 MoI) Chlorid der 4-Chlorbuttersäure in 50 ml wasserfreiem Dioxan unter Eiskühlung zugesetzt. Danach wird die Reaklionslösung noch weitere 10 Minuten bei Zimmertemperatur gerührt und der entstandene Niederschlag filtriert. Man erhält 8 g Glycinamid · HCI. Das Lösungsmittel Dioxan wird durch Destillation im Vakuum entfernt und das Produkt mit Äther aus dem Rückstand abgeschieden. Man erhä-'". 10,5 g (78%) des Produktes. Fn 123-125"C.11.1 g (0.15 mol) of glycinamide are dissolved in 50 ml of NN-dimelhylacetäifiid with gentle warming and 1055 g (0.075 mol) of chloride of 4-chlorobutyric acid in 50 ml of anhydrous dioxane are added to the solution with ice cooling. The reaction solution is then stirred for a further 10 minutes at room temperature and the precipitate formed is filtered off. 8 g of glycinamide · HCl are obtained. The solvent dioxane is removed by distillation in vacuo and the product is separated off from the residue with ether. One obtains 10.5 g (78%) of the product. F n 123-125 "C.

Das Produkt zeigt im Dünnschichtchromatogramm auf Silicagel nil Mcthylenchlorid-AcetonMclhanol = 5:5:1 nur einen Fleck bei Rf 0,43 (Nachweis durch Besprühen mit Jod).In the thin-layer chromatogram on silica gel, the product shows methylene chloride-acetone-methanol = 5: 5: 1 only one spot at Rf 0.43 (detection by spraying with iodine).

Zu Analysen/wecken wird das Produkt aus einer Mischung von Aceton mit Hexan oder Äthylacetat umkristallisiert, wobei farblose Plättchen erhallen werden. Fp 128- 130"C.For analyzes / awakening, the product is made from a mixture of acetone with hexane or ethyl acetate recrystallized, whereby colorless platelets are resurrected. M.p. 128-130 "C.

Analyse: C6H11NjO2Ci(178.62)Analysis: C 6 H 11 NjO 2 Ci (178.62)

Berechnet: C 4034, H 6,21, N 15,68%;
gefunden: C 40.46, 1-15,97, N 15,54%.
Calculated: C 4034, H 6.21, N 15.68%;
found: C 40.46, 1-15.97, N 15.54%.

IR-SpeklfUm(crh '):IR-SpeklfUm (crh '):

3400,3310,320Ö(NH2iNI I),
1680-1620(C = O, priili. +sck. Amid),
6S 1550-1530 (sek. Amid)
3400,3310,320Ö (NH 2i NI I),
1680-1620 (C = O, priili. + Sck. Amide),
6 S 1550-1530 (sec. Amide)

Das erfihdtingsgemäßc Verfahren wird anhand der folgenden Beispiele näher erläutert:The process according to the invention is explained in more detail using the following examples:

5555

Beispiel 1example 1

2-Oxo-1 -pyrrolidin-acetamid durch Cyclisieren
von 4-ChIorbutyryIgIycinamid mit NaOH.
2-Oxo-1-pyrrolidine-acetamide by cyclization
of 4-chlorobutyryIgIycinamide with NaOH.

10 g (0,056 Mol) 4-Chlorbutyrylglycinamid werden unter Erwärmen bis zu 50° C in 100 ml wasserfreiem, Äthanol gelöst und der Lösung 5,9 ml In Natriumhydroxid in Äthanol (0,056 Mol) unter Rühren tropfenweise zugefügt. Die Reaktionslösung wird 10 Minuten unter Rückflußkühlung bis zum Sieden erhitzt. Nach Abkühlung wird das entstandene Natriumchlorid (2^5 g, 89%) durch Filtration abgetrennt. Nach Entfernen des Lösungsmittels erhält man durch Zusatz von Isopropanol zum öligen Rückstand 6,9 g (86%) des weißen, kristallinen Produktes, Fp 145 - 147° C.10 g (0.056 mol) of 4-chlorobutyrylglycine amide are dissolved in 100 ml of anhydrous ethanol with heating up to 50 ° C. and 5.9 ml of sodium hydroxide in ethanol (0.056 mol) are added dropwise to the solution with stirring. The reaction solution is refluxed for 10 minutes and heated to boiling. After cooling, the sodium chloride formed (2 ^ 5 g, 89%) is separated off by filtration. After removal of the solvent, by the addition of isopropanol to the oily residue 6.9 g (86%) of white crystalline product, mp p 145-147 ° C.

Beispiel 2Example 2

2-Oxo-l-pyr-olidin-acetamid durch Cyclisieren
nut Natrium-tert-Butylat
2-Oxo-1-pyr-olidine-acetamide by cyclization
only sodium tert-butoxide

4 g (0,022 MoI) 4-Chlorbutyrylglycinamid werden in 80 ml Dioxan unter Erwärmen gelöst. Zur Lösung gibt man unter Rühren eine Suspension von 0,022 MoI Natrium-tert.-Butylat in 20 ml wasserfreiem Dioxan. Die Mischung wird bei Raumtemperatur eine Stunde gerührt, der Niederschlag (1,2 g, (94%)) durch Filtration abgetrennt Die Mutterlauge wird bis zur Trockne eingedampft und das Rohprodukt aus Isopropanol kristallisiert, wodurch 2 24 g (72%) des Produktes erhalten werden, Fp 146- 149°C.4 g (0.022 mol) of 4-chlorobutyrylglycine amide are dissolved in 80 ml of dioxane with heating. A suspension of 0.022 mol of sodium tert-butoxide in 20 ml of anhydrous dioxane is added to the solution with stirring. The mixture is stirred at room temperature for one hour, the precipitate (1.2 g, (94%)) separated by filtration. The mother liquor is evaporated to dryness and the crude product is crystallized from isopropanol, giving 224 g (72%) of the product are F p 146- 149 ° C.

Auf analoge Weise läßt sich die Ringschlußreaktion von 4-Chlorbutyrylglycinamid mit Natriummethylat oder -äthylat durchführen.The ring closure reaction of 4-chlorobutyrylglycine amide with sodium methylate can be carried out in an analogous manner or ethylate.

Beispiel 3Example 3

2-Oxo-l-pyrrolidin-acetamid durch Cyclisieren von2-Oxo-l-pyrrolidine-acetamide by cyclizing

ίο 4-ChIor-butyryIglycinamid unter Anwendung eines Anionenaustauschers.ίο 4-chloro-butyryIglycinamid using a Anion exchanger.

2,2 g (0,0124MoI) 4-Chlorbutyrylglycinamid werden in 15 ml wasserfreiem Äthanol gelöst und *.u einer Suspension des Ionenaustauschers Dowex 1 in Äthanol2.2 g (0.0124MoI) of 4-chlorobutyrylglycine amide are dissolved in 15 ml of anhydrous ethanol and * .u one Suspension of the ion exchanger Dowex 1 in ethanol

π gegeben. Die Suspension enthält 20 ml des trockenen Ionenaustauschers Dowex 1 in der OH-Form in 30 ml wasserfreiem Äthanol. Das Reaktionsgemisch wird eine Stunde bei einer Temperatur von 20 —25° C gerührt Anschließend wird der Austauscher abdekantiert undgiven π. The suspension contains 20 ml of the dry Ion exchanger Dowex 1 in the OH form in 30 ml of anhydrous ethanol. The reaction mixture becomes a Stirred for an hour at a temperature of 20-25 ° C The exchanger is then decanted and

»u mit 20 ml Äthanol gewaschen. Das gesamte Athanui wird dann abgedampft Aus dem festen Rückstand erhält man durch Umkristallisation aus Isopropanol 1,25 g (71%) des Produktes, Fp 145- 147° C.»U washed with 20 ml of ethanol. The whole is then evaporated Athanui is obtained from the solid residue by recrystallization from isopropanol 1.25 g (71%) of product, F p 145- 147 ° C.

Auf analoge Weise erhält man ein wesentlich reineres Rohprodukt nach Umkristallisation aus Isopropanol in Ausbeuten von 85% mit einem Fp von 148—1503C, wenn man mit einer mit dem Austauscher gefüllten Kolonne arbeitet.In an analogous manner, a much purer crude product is obtained after recrystallization from isopropanol in yields of 85% with an mp of 148-150 3 C when working with a column filled with the exchanger.

Claims (1)

Patentanspruch: »Verfahren zur Herstellung von 2-Oxo-l-pyrrolidin-acetamid der FormelClaim: »Process for the preparation of 2-oxo-l-pyrrolidine acetamide of the formula CH,-CONH2 CH, -CONH 2 dadurch gekennzeichnet, daß man 4-Chlor-butyIrylgIycinamid in einem organischen Lösungsmittel löst und in Gegenwart von NaOH, eines Natriumalkoholats oder eines basischen Ionenaustauschers des Typs Dowex 1 bei einer Temperatur ab 200C cyclisierL«characterized in that 4-chloro-butyIrylgIycinamid is dissolved in an organic solvent and cyclized in the presence of NaOH, a sodium alcoholate or a basic ion exchanger of the Dowex 1 type at a temperature from 20 0 C "
DE2759297A 1976-01-14 1977-01-14 Process for the preparation of 2-oxo-1-pyrrolidine-acetamide Expired DE2759297C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
YU7776A YU39660B (en) 1976-01-14 1976-01-14 Process for obtaining 2-oxo-1-pyrrolidine acetamide
YU198376A YU40148B (en) 1976-08-11 1976-08-11 Process for preparing n-subtituted amides of 2-oxo-pyrrolidines

Publications (2)

Publication Number Publication Date
DE2759297B1 DE2759297B1 (en) 1979-07-19
DE2759297C2 true DE2759297C2 (en) 1980-04-03

Family

ID=27130704

Family Applications (2)

Application Number Title Priority Date Filing Date
DE2701450A Expired DE2701450C2 (en) 1976-01-14 1977-01-14 Process for the preparation of N-substituted amides of 2-oxo-1-pyrrolidine
DE2759297A Expired DE2759297C2 (en) 1976-01-14 1977-01-14 Process for the preparation of 2-oxo-1-pyrrolidine-acetamide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE2701450A Expired DE2701450C2 (en) 1976-01-14 1977-01-14 Process for the preparation of N-substituted amides of 2-oxo-1-pyrrolidine

Country Status (12)

Country Link
JP (1) JPS603320B2 (en)
AT (1) AT360980B (en)
CH (1) CH627742A5 (en)
DD (1) DD128591A5 (en)
DE (2) DE2701450C2 (en)
FI (1) FI66846C (en)
FR (1) FR2344535A1 (en)
GB (2) GB1549755A (en)
HU (1) HU173642B (en)
NL (1) NL7700408A (en)
PL (1) PL102996B1 (en)
SE (1) SE415972B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1539817A (en) * 1976-10-22 1979-02-07 Ucb Sa N-substituted lactams
FI840261A (en) * 1983-01-27 1984-07-28 Ciba Geigy Ag SUBSTITUTE PYRROLIDINONDERIVAT OCH FOERFARANDE FOER DERAS FRAMSTAELLNING.
FI840260A (en) * 1983-01-27 1984-07-28 Ciba Geigy Ag PYRROLIDINONDERIVAT OCH FOERFARANDE FOER DERAS FRAMSTAELLNING.
IT1190378B (en) * 1985-06-21 1988-02-16 Isf Spa PYROLIDONIC DERIVATIVES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3250784A (en) * 1963-12-23 1966-05-10 Gen Aniline & Film Corp Pyrrolidonyl-gamma-butyramide and process of preparing
GB1039113A (en) * 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
GB1361388A (en) * 1970-08-05 1974-07-24 Geistlich Soehne Ag Ny--sulphamoylaryl--pyrrolidines
FR2363474A1 (en) * 1976-09-03 1978-03-31 Doris Dev Richesse Sous Marine Sea bed anchor placing system - uses hydraulic motor driven borer at end of chain which carries pairs of pivoted flukes (NO 28.3.78)

Also Published As

Publication number Publication date
PL102996B1 (en) 1979-05-31
JPS52116462A (en) 1977-09-29
FI66846C (en) 1984-12-10
DD128591A5 (en) 1977-11-30
FR2344535A1 (en) 1977-10-14
GB1549754A (en) 1979-08-08
GB1549755A (en) 1979-08-08
FI66846B (en) 1984-08-31
PL195311A1 (en) 1978-02-27
AT360980B (en) 1981-02-10
ATA4377A (en) 1979-07-15
HU173642B (en) 1979-07-28
NL7700408A (en) 1977-07-18
FR2344535B1 (en) 1982-10-08
JPS603320B2 (en) 1985-01-26
FI770087A (en) 1977-07-15
DE2701450C2 (en) 1984-10-18
DE2701450A1 (en) 1977-07-21
CH627742A5 (en) 1982-01-29
DE2759297B1 (en) 1979-07-19
SE7700173L (en) 1977-07-15
SE415972B (en) 1980-11-17

Similar Documents

Publication Publication Date Title
AT363096B (en) METHOD FOR PRODUCING NEW PHTHALAZINE DERIVATIVES AND THEIR SALTS
EP0084164B1 (en) Derivatives of bicyclic amino acids, process for their preparation, agents containing them and their use, as well as bicyclic amino acids as intermediates, and process for preparing them
DE2705025A1 (en) XANTHIN DERIVATIVES, THE METHOD OF MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THEM
DE2918261C2 (en)
DE68912860T2 (en) 1 - [(Diarylmethoxy) alkyl] pyrrolidines and piperidines, process for their preparation and medicaments containing them.
DE69116237T2 (en) Derivatives of hexahydroazepine, process for their preparation and medicinal products containing them
DE2759297C2 (en) Process for the preparation of 2-oxo-1-pyrrolidine-acetamide
AT399337B (en) 2-SUBSTITUTED N, N'-DITRIMETHOXYBENZOYLPIPERAZINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR THERAPEUTIC COMPOSITIONS
DD229402A5 (en) METHOD FOR THE PRODUCTION OF PIPERIDINION DERIVATIVES THAT, AS MYOCARD PROTECTION, REPRESENT ANTIARRHYTMIC ACTIVITY
DE2044172A1 (en) New pyrrole derivatives, a process for their production and their use in pharmaceutical preparations
DE3226921C2 (en) New 3,7-diazabicyclo [3.3.1] nonane compounds and process for their preparation
DE2829821C2 (en) R, S-N- [1-phenyl-2- (2-hydroxyethylamino) ethyl] - dithiocarbamic acid, and their allyl, propargyl and benzyl esters and processes for their preparation
DE2336670A1 (en) AMINO ETHERS OF O-THYMOTIC ACID ESTERS
DD142876A5 (en) PROCESS FOR THE PREPARATION OF PYRROLIDINCARBOXALDEHYDE AND PIPERIDINCARBOXALDEHYDE DERIVATIVES
DD153549A5 (en) PROCESS FOR THE PREPARATION OF PYRIDINE DERIVATIVES
DE2110169C3 (en) N-G, 3-Diphenylcyclopropyl) glycine amides and processes for their preparation
DE2627190A1 (en) NEW FUENFRING COMPOUNDS, METHODS OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
DE3813416A1 (en) 3,4-DIHYDROXYPYRROLIDIN-2-ON DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THE AGENTS CONTAINING THEM AND THEIR USE, AND THE NEW INTERMEDIATES WHICH ARE INVOLVED IN THE MANUFACTURE
DE2122070A1 (en) 1 Veratryl 4 methyl 5 ethyl 7,8 dimethoxy 2,3 diazabicyclo square brackets to 5,4,0 square brackets to undeca pentaen (1,3,6,8,10) and its use
DE3102768A1 (en) "CINNAMYLMORANOLINE DERIVATIVES"
DE3442365A1 (en) NEW AZABICYCLIC COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
EP0266711A1 (en) 2,6-Diamino-3-halobenzyl-pyridines and process for their preparation as well as their use in pharmaceuticals
AT372945B (en) METHOD FOR PRODUCING NEW NSUBSTITUTED MORANOLINE DERIVATIVES
DE2914805A1 (en) TETRAHYDROALSTONE DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THEM
DE2302671A1 (en) 5-ACYL PYRROLE, THE METHOD OF MANUFACTURING IT AND ITS USE IN MEDICINAL PRODUCTS

Legal Events

Date Code Title Description
OI Miscellaneous see part 1
OI Miscellaneous see part 1
OD Request for examination
8328 Change in the person/name/address of the agent

Free format text: VON FUENER, A., DIPL.-CHEM. DR.RER.NAT. EBBINGHAUS, D., DIPL.-ING. FINCK, K., DIPL.-ING. DR.-ING., PAT.-ANW., 8000 MUENCHEN

8339 Ceased/non-payment of the annual fee